Appropriate Use Criteria for <sup>18</sup>F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease
Hossein Jadvar(Society of Nuclear Medicine and Molecular Imaging), Landis K. Griffeth(Society of Nuclear Medicine and Molecular Imaging), Patrick M. Colletti(University of Southern California), Helen Nadel(Helios Klinikum Emil von Behring), Bernd J. Krause(University of Rostock), David I. Quinn(USC Norris Comprehensive Cancer Center), Eric Rohren(Society of Nuclear Medicine and Molecular Imaging), Giuseppe Esposito(National Institutes of Health), Katherine Zukotynski(Unknown), Rathan M. Subramaniam(Dunedin Public Hospital), Julie Kauffman(Society of Nuclear Medicine and Molecular Imaging), Roberto C. Delgado Bolton(Hospital San Pedro), Sukhjeet Ahuja(Society of Nuclear Medicine and Molecular Imaging), Andrei Iagaru(Stanford University)
Cited by 99
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
|New England Journal of Medicine|2013|568
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|507